SCHEMBL6192241

SCHEMBL6192241

CCOC(=O)N1C=CC=NC1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
FAAH O00519 1/20 0.33
MGLL Q99685 1/20 0.33
ALDH1A1 P00352 4/20 0.33
POLB P06746 2/20 0.33
HTT P42858 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
MAPT P10636 2/20 0.32
ABL1 P00519 1/20 0.32
RIN1 Q13671 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
LMNA P02545 3/20 0.31
KDM4E B2RXH2 2/20 0.31
HSD17B10 Q99714 1/20 0.31
GAA P10253 2/20 0.31
RECQL P46063 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28171235 0.88 ALDH1A1 (0.32) TSHRALDH1A1POLBSMN1; SMN2TDP1
Hydrochloric Acid SCHEMBL28171965 0.87 ALDH1A1 (0.31) ALDH1A1LMNA
SCHEMBL6252891 0.83 ALDH1A1 (0.34) TSHRALDH1A1SMN1; SMN2GAA
SCHEMBL28798967 0.83
SCHEMBL6252532 0.83 TSHR (0.33) TSHR
SCHEMBL30393948 0.80 TSHR (0.31) TSHR
SCHEMBL29673007 0.71 SOAT1 (0.34) TSHRFAAHMGLLALDH1A1POLB
SCHEMBL4436164 0.71
SCHEMBL932027 0.71
SCHEMBL4771331 0.70 TSHR (0.35) TSHRMEN1KMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116265467-B Intermediate for synthesizing TYK2 inhibitor, and preparation method and application thereof 成都科岭源医药技术有限公司 2025-04-18 CN disclosed
CN-116829562-B Macrocyclic compound, pharmaceutical composition and application thereof 深圳国顺康医药科技有限公司 2025-04-01 CN disclosed
CN-113527298-B Macrocyclic lactam derivatives, preparation method and application thereof 浙江海正药业股份有限公司 2025-01-03 CN disclosed
US-20240270759-A1 Preparation of SHP2 phosphatase inhibitors and its applications YA THERAPEUTICS INC (CN) 2024-08-15 US disclosed
CN-117886813-A SHP2 phosphatase allosteric inhibitors 药雅科技(上海)有限公司 2024-04-16 CN disclosed
CN-115232144-B Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof 长春金赛药业有限责任公司 2024-04-02 CN disclosed
CN-117756848-A TH-302 derivative and preparation method thereof 常州大学 2024-03-26 CN disclosed
CN-113727984-B Macrocyclic derivatives, preparation method and application thereof 浙江海正药业股份有限公司 2024-03-15 CN disclosed
CN-112204029-B Therapeutic compounds 豪夫迈·罗氏有限公司 2024-03-01 CN disclosed
CN-115052660-B Substituted 7- (methylamino) pyrazolo [1,5-a ] pyrimidine-3-carboxamide derivatives 伊莱利利公司 2024-01-09 CN disclosed
WO-2019233461-A1 TROPOMYOSIN RECEPTOR KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏威凯尔医药科技有限公司 (CN) 2019-12-12 WO disclosed
CN-109715165-A Huge ring kinase inhibitor TP生物医药公司 2019-05-03 CN disclosed
CN-108473498-A Pyrazolo [1,5a] pyrimidine derivatives as IRAK4 conditioning agents 豪夫迈·罗氏有限公司 2018-08-31 CN disclosed
CN-104910161-B Pyrazolopyrimidine compound and method as JAK inhibitor 健泰科生物技术公司 2018-03-30 CN disclosed
CN-107735399-A The big ring of chiral diaryl as the conditioning agent of protein kinase TP生物医药公司 2018-02-23 CN disclosed
CN-107108638-A Piperidyl PyrazolopyrimidinonecGMP and application thereof 拜耳制药股份公司 2017-08-29 CN disclosed
CN-1771231-B Calcium receptor modulating compounds and uses thereof TAKEDA CHEMICAL INDUSTRIES LTD 2011-05-25 CN disclosed
CN-1771231-A Calcium receptor modulating compounds and uses thereof TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2006-05-10 CN disclosed
EP-1511751-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS Neogenesis Pharmaceuticals, Inc. (US) 2005-03-09 EP disclosed
WO-2003101993-A1 PYRAZOLO` 1,5A! PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS NEOGENESIS PHARMACEUTICALS, INC. (US) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270759-A1 Preparation of SHP2 phosphatase inhibitors and its applications PTPN2, PTPN22, PTPN5 TSHR 988/4885MEN1 974/4885KMT2A 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.